Dr. Nadiesda Costa, Associate Professor of Medicine, Medstar Georgetown University Hospital, discusses her role as Principal Investigator for our Phase II trial for potravitug, a highly potent therapeutic antibody targeting…
Dr. David Wojciechowski, Medical Director of the Kidney Transplant Program at the University of Texas Southwestern, discusses his involvement as Site Principal Investigator for our Phase II trial for potravitug,…
– Results show biopsy-proven resolution of BK polyomavirus nephropathy in kidney transplant recipients – No safety or tolerability concerns were observed – Supports progression into Phase III development with the…
Novel antibody, potravitug, demonstrates high neutralization of all BKPyV serotypes with potential to transform treatment for kidney transplant recipients with BKPyV infection Schlieren / Zurich, Switzerland, 22 July, 2025 –…
1. Please introduce yourself and tell us about your background spanning both academia and industry, particularly your role in the Transplant Therapeutics Consortium (TTC). I am William Fitzsimmons, a pharmacist…
Schlieren / Zurich, Switzerland, 19 June, 2025 – Memo Therapeutics AG ( “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer,…
Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier This proof-of-concept study…
1. Please introduce yourself to our audience and share with us a bit about your journey with kidney disease. Good day everyone, I’m Richard Knight, currently a Lecturer at Bowie…
Background Lyfebulb, founded in 2014 by Karin Hehenberger, is an organisation with a mission to reduce the burden of chronic disease through the power of the patient. In March 2024,…
Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren / Zurich, Switzerland, 4…
Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer,…
1. What influenced your transition from a career in the pharmaceutical industry to patient advocacy? Professionally, I came to a fork in the road in my career. I took inventory…
Archived press releases
Memo Therapeutics AG’s assets not related to potravitug, will be transferred to a newly incorporated company, Memorises Bio, retained by Memo Therapeutics AG’s shareholders.
This archive will be maintained until the launch of the Memorises Bio website. For information regarding topics unrelated to potravitug, please contact the Memorises Bio team.
– Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology– Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by CSL, a license…
1. Can you talk a bit about how your scientific training and industry experience led to your current role at Memo Therapeutics AG? I’m a bioengineer by training, and the…